Equest, Inc. – Trademark Portfolio

Entity Type: 03

Equest, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include EQUI-SPAZ. The owner is based in Plano, TX.

3330 San Gabriel Dr.

Plano, TX 75074

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EQUI-SPAZ
EQUI-SPAZ
Registered 1991
MEDI-VET
MEDI-VET
Cancelled 1991
M.A.C.
M.A.C.
Cancelled 1990
RE-COUP
RE-COUP
Cancelled 1985
EQUEST
EQUEST
Cancelled 1984

Trademark Classifications

Equest, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does Equest, Inc. have?

Equest, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 6 cancelled.

What trademark classes does Equest, Inc. file in?

Equest, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Equest, Inc.'s most well-known trademarks?

Equest, Inc.'s registered trademark portfolio includes well-known marks such as EQUI-SPAZ. These are among 1 currently registered trademark in the portfolio.

What is Equest, Inc.'s trademark registration success rate?

Equest, Inc. has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.